A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Public ClinicalTrials.gov record NCT00991172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2, randomized, double-blind, parallel-group, single dose study to evaluate the safety and efficacy of 2 dose levels of REGN475 compared with placebo in patients with sciatic pain. Enrollment of approximately 50 patients in each of the 3 treatment arms is expected at up to 35 US sites, for a total enrollment of approximately 150 patients. Patients will receive 1 injection under the skin of either active or placebo REGN475, and be followed over 10 visits for 12 weeks.
Study identification
- NCT ID
- NCT00991172
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- May 2010 (Actual)
- Completion
- May 2010 (Actual)
- Last update posted
- Dec 8, 2011
2009 – 2010
United States locations
- U.S. sites
- 30
- U.S. states
- 18
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Investigational Site | Birmingham | Alabama | — | — |
| Regeneron Investigational Site | Mobile | Alabama | — | — |
| Regeneron Investigational Site | Peoria | Arizona | — | — |
| Regeneron Investigational Site | Anaheim | California | — | — |
| Regeneron Investigational Site | Beverly Hills | California | — | — |
| Regeneron Investigational Site | National City | California | — | — |
| Regeneron Investigational Site | Santa Ana | California | — | — |
| Regeneron Investigational Site | Milford | Connecticut | — | — |
| Regeneron Investigational Site | Stamford | Connecticut | — | — |
| Regeneron Investigational Site | Clearwater | Florida | — | — |
| Regeneron Investigational Site | Hallandale | Florida | — | — |
| Regeneron Investigational Site | St. Petersburg | Florida | — | — |
| Regeneron Investigational Site | Tampa | Florida | — | — |
| Regeneron Investigational Site | West Palm Beach | Florida | — | — |
| Regeneron Investigational Site | Atlanta | Georgia | — | — |
| Regeneron Investigational Site | Sandy Springs | Georgia | — | — |
| Regeneron Investigational Site | Overland Park | Kansas | — | — |
| Regeneron Investigational Site | Rockville | Maryland | — | — |
| Regeneron Investigational Site | Kansas City | Missouri | — | — |
| Regeneron Investigational Site | Albuquerque | New Mexico | — | — |
| Regeneron Investigational Site | Raleigh | North Carolina | — | — |
| Regeneron Investigational Site | Cincinnati | Ohio | — | — |
| Regeneron Investigational Site | Duncansville | Pennsylvania | — | — |
| Regeneron Investigational Site | Tyrone | Pennsylvania | — | — |
| Regeneron Investigational Site | Warwick | Rhode Island | — | — |
| Regeneron Investigational Site | Greer | South Carolina | — | — |
| Regeneron Investigational Site | Memphis | Tennessee | — | — |
| Regeneron Investigational Site | El Paso | Texas | — | — |
| Regeneron Investigational Site | San Antonio | Texas | — | — |
| Regeneron Invesitgational Site | West Jordan | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00991172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2011 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00991172 live on ClinicalTrials.gov.